In patients treated with opioid therapy for chronic pain, the legalization of recreational cannabis does not affect compliance rate, a new study found. Researchers conducted a retrospective cohort study on results from a “high-risk” urine drug testing panel. Results from 1 year before and 1 year after initiation of recreational cannabis legislation were analyzed. The testing panel included qualitative assays for cannabinoids and 9 other common drugs of abuse, in addition to a quantitative LC-MS/MS assay for 23 different opioids and metabolites. They found:
- In the pre-legalization period, 1,776 panels were performed; 1,648 panels were performed post-legalization.
- An increase in the rate of positive cannabinoid results was observed after legalization of recreational cannabis.
- However, the overall compliance rate was consistent.
Lo SY, Winston-McPherson GN, Starosta AJ, et al. Cannabis legalization does not influence patient compliance with opioid therapy. [Published online ahead of print November 10, 2018]. Am J Med. doi:10.1016/j.amjmed.2018.11.002.
This Week's Must Reads
Acute Illness and Cannabis Use in Adults, Ann Intern Med; ePub 2019 Mar 26; Monte, et al
Must Reads in Pain
Sleep Disturbance and Chronic Pain Intensity, Clin J Pain; ePub 2019 Mar 25; Burgess, et al
Dual Receipt of Rx Opioids & Overdose Death, Ann Intern Med; ePub 2019 Mar 12; Moyo, et al
Opioid-Related Mortality in US by Opioid Type, JAMA Netw Open; 2019 Feb 22; Kiang, et al
Disparities in the Prescription of Opioids, JAMA Intern Med; ePub 2019 Feb 11; Friedman, et al
Trends in Pain Prevalence in US Adults, J Pain; ePub 2019 Jan 15; Nahin, et al